(Total Views: 170)
Posted On: 03/02/2019 10:39:32 AM
Post# of 155005
I am very optimistic also. I feel a few years from now, we are going to be using leronlimab commercially with lots of ccr5+ cancers. 15B+ sales and climbing... but just my opinion.
Yes, I also noticed NP saying that. Maybe misiu will respond with an opinion, she knows more about the tnbc trial then anyone outside of cydy's people imo.
But in the original PR, they mention an initial readout and also filing BTD if original results are good.
"CytoDyn has identified five clinical trial sites and intends to dose its first several patients and expects to have initial readout during the first quarter of 2019. The change in circulating tumor cells (CTCs) number will be evaluated every 21 days during treatment and will be used as an initial prognostic marker for efficacy."
Yes, I also noticed NP saying that. Maybe misiu will respond with an opinion, she knows more about the tnbc trial then anyone outside of cydy's people imo.
But in the original PR, they mention an initial readout and also filing BTD if original results are good.
"CytoDyn has identified five clinical trial sites and intends to dose its first several patients and expects to have initial readout during the first quarter of 2019. The change in circulating tumor cells (CTCs) number will be evaluated every 21 days during treatment and will be used as an initial prognostic marker for efficacy."
(0)
(0)
